StemCell Therapy

August 10, 2017 - By Louis Casey

Investors sentiment decreased to 0.3 in Q4 2016. Its down 0.37, from 0.67 in 2016Q3. It turned negative, as 16 investors sold Neuralstem, Inc. shares while 11 reduced holdings. 2 funds opened positions while 6 raised stakes. 6.88 million shares or 44.05% less from 12.30 million shares in 2016Q3 were reported.Fifth Third Bank & Trust accumulated 120,000 shares. Moreover, Northern has 0% invested in Neuralstem, Inc. (NASDAQ:CUR). Geode Capital Mgmt Limited Liability Company, Massachusetts-based fund reported 1.03 million shares. Blair William Il holds 0% or 418,942 shares. National Bank Of Mellon Corp owns 0% invested in Neuralstem, Inc. (NASDAQ:CUR) for 91,969 shares. California Public Employees Retirement invested in 155,700 shares. Wells Fargo And Mn stated it has 0% in Neuralstem, Inc. (NASDAQ:CUR). Vanguard Group Incorporated Inc invested in 3.09 million shares or 0% of the stock. The California-based Blackrock Institutional Na has invested 0% in Neuralstem, Inc. (NASDAQ:CUR). National Asset Mgmt Incorporated invested in 0.01% or 167,500 shares. Natl Bank Of America Corp De, North Carolina-based fund reported 8,400 shares. Blackrock Advisors reported 17,361 shares. First Heartland Consultants accumulated 10,000 shares. Kcg Holding reported 0% in Neuralstem, Inc. (NASDAQ:CUR). Gru One Trading L P accumulated 4,349 shares.

Since February 24, 2017, it had 3 buys, and 0 insider sales for $70,004 activity. LLOYD JONES JONATHAN BRIAN had bought 5,455 shares worth $30,003. 7,500 shares were bought by Daly Richard J, worth $30,000.

The stock of Neuralstem Incorporated (NASDAQ:CUR) registered an increase of 0.98% in short interest. CURs total short interest was 942,000 shares in August as published by FINRA. Its up 0.98% from 932,900 shares, reported previously. With 90,000 shares average volume, it will take short sellers 11 days to cover their CURs short positions. The short interest to Neuralstem Incorporateds float is 11.11%.

It closed at $1.08 lastly. It is down 3.35% since August 10, 2016 and is uptrending. It has underperformed by 13.35% the S&P500.

Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $13.09 million. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. It currently has negative earnings. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

More notable recent Neuralstem, Inc. (NASDAQ:CUR) news were published by: Globenewswire.com which released: Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical on August 08, 2017, also Seekingalpha.com with their article: Neuralstem Is Doomed published on August 03, 2017, Globenewswire.com published: Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants on July 27, 2017. More interesting news about Neuralstem, Inc. (NASDAQ:CUR) were released by: Globenewswire.com and their article: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into published on August 02, 2017 as well as Benzinga.coms news article titled: Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
What Will Happen to Neuralstem Incorporated (NASDAQ:CUR) Next? The Stock Has Increase in Shorts - BZ Weekly

This entry was posted on August 10, 2017 at 2:42 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |